A Homogeneous in Vitro Functional Assay for Estrogen Receptors: Coactivator Recruitment
Jianwei Liu,
Katharine S. Knappenberger,
Helena Käck,
Gunilla Andersson,
Ewa Nilsson,
Christine Dartsch and
Clay W. Scott
AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850 (J.L., K.S.K., C.W.S.); 431 83 Mölndal, Sweden (H.K., G.A., E.N.); and 151 85 Södertälje, Sweden (C.D.)
Address all correspondence and requests for reprints to: Jianwei Liu, AstraZeneca Pharmaceuticals, 1800 Concord Pike, LW207D, Wilmington, Delaware 19850. E-mail: jianwei.liu{at}astrazeneca.com.
 |
ABSTRACT
|
---|
Estrogen receptor (ER)-mediated gene transcription occurs via the formation of a multimeric complex including ligand-activated receptors and nuclear coactivators. We have developed a homogeneous in vitro functional assay to help study the ligand-dependent interaction of ERs with various nuclear coactivators. The assay consists of FLAG-tagged ER
or ERß ligand binding domain (LBD), a biotinylated coactivator peptide, europium-labeled anti-FLAG antibody, and streptavidin-conjugated allophycocyanin. Upon agonist binding, the biotinylated coactivator peptide is recruited to FLAG-tagged ER LBD to form a complex and thus allow fluorescence resonance energy transfer (FRET) to occur between europium and allophycocyanin. Compounds with estrogen antagonism block the agonist-mediated recruitment of a coactivator and prevent FRET. The assay was used to evaluate the preference of ERs for various coactivators and ligands. Both ER
and ERß exhibited strong preferences for coactivator peptides corresponding to steroid receptor coactivator-1 and PPAR
coactivor-1 vs. peroxisome proliferator-activated receptor-interacting protein and cAMP response element binding protein-binding protein. 17ß-Estradiol acted as a nonselective agonist for ER
and ERß. Genistein showed full agonism for ER
and only partial agonism for ERß, but with higher potency for ERß than ER
. Both raloxifene and tamoxifen behaved as full antagonists in this functional assay. The results obtained using compounds with a wide range of potency correlated well with those from a cell-based reporter gene assay. Therefore, this simple in vitro functional assay is predictive of ligand-dependent transactivation function of the receptor and, as such, is useful in nuclear receptor applications including mechanistic studies.
 |
INTRODUCTION
|
---|
NUCLEAR RECEPTORS (NRs) constitute a large family of ligand-activated transcription factors. Their activities are governed by their cognate ligands and through interaction with components of the transcriptional machinery. Nuclear steroid hormone receptors comprise the type I subfamily of NRs and are key mediators in the endocrine signaling pathways, playing an important role in the control of differentiation, growth, and metabolic homeostasis (1). Estrogen receptors (ERs) are members of this subfamily and are important pharmaceutical targets for hormone replacement in menopausal women and for chemotherapeutic drugs against certain reproductive cancers. Some compounds such as tamoxifen and raloxifene have been termed selective ER modulators (SERMs) because they reveal both ER agonist and antagonist activity in a cell type- and promoter-specific manner. In theory, SERMs with ER estrogenic activity in bone, brain, and liver (for lipid metabolism) but without effect on the endometrium, and the breast will be potentially ideal for postmenopausal hormone replacement treatment.
The ER domain structure is typical of NRs. The amino-terminal region is involved in transactivation of gene expression and has been termed the activation function domain, or AF1 domain. The middle region contains a two-zinc finger structure, which plays an important role in binding to specific DNA response elements and in receptor dimerization. The carboxyl-terminal region also contains an activation function domain, termed AF2. Within AF2 lies a ligand-binding domain (LBD) that is crucial for binding of receptor specific ligands and also corepressors and coactivators. These binding interactions affect receptor dimerization, nuclear translocation, and modulation of target gene expression by AF2 (2, 3).
The LBD is structurally conserved among the NR family and consists of between 10 and 12
-helices folded in a globular domain (4). A central hydrophobic pocket accommodates the cognate ligand, which upon binding induces a conformational change in the LBD, exposing a coactivator-docking site on the LBD surface. The subsequent recruitment of coactivators to the NR promotes transactivation. However, the binding of raloxifene or tamoxifen to ERs results in a different conformation change in which the coactivator-binding site is blocked from interaction with a coactivator, thereby blocking AF2-mediated transcriptional activity.
Several classes of NR coactivators (NCoA) interact with ERs (5). One class consists of the cAMP response element binding protein-binding protein (CBP) and the related factor, p300. These molecules promote the transcription of NR-responsive genes as well as cAMP response element binding protein-binding protein and activator protein-1-responsive genes, and therefore may integrate multiple signal transduction pathways (6, 7). A second class of coactivator proteins is called steroid receptor coactivators (SRC) and includes SRC1/NCoA1, SRC2/transcriptional intermediary factor 2 (TIF2)/glucocorticoid receptor interacting protein (GRIP)/NCoA2, and SRC3/receptor-associated coactivator 3 (RAC3)/p300/CBP-cointegrator-associated protein (pCIP)/activator for TR (ACTR)/amplified in breast cancer 1 (AIB1)/TR-associated molecule-1 (TRAM-1)/NCoA3 (8). These three proteins also interact with CBP/p300 in ligand-dependent transactivation by NRs. SRC1s role appears to be restricted to NRs. Two isoforms of SRC1 have been identified: SRC1a and SRC1e. These isoforms have divergent sequence at their C- termini and differ in their ability to enhance ER-driven transactivation (9). In vitro studies indicate that SRC3 enhances the transcriptional activity of ER
, but not ERß (10). Other coactivators that have been shown to interact with NRs include PRIP [peroxisome proliferator-activated receptor (PPAR) interacting protein]/RAP250 (11, 12) and PGC-1 (PPAR
coactivor-1; Ref. 13).
All nuclear coactivators contain one or more copies of the highly conserved LXXLL amphipathic
-helix motif, also called the NR box or NRB. The NRB resides within a larger domain termed the nuclear receptor interaction domain, or NRID, that directly binds to hormone-liganded NRs. For example, Zhou et al. (14) used NRIDs from CBP and SRC-1 in a coactivator FRET assay and showed that both interacted with PPAR
and ER
but with differing affinities: the CBP NRID had a higher affinity for PPAR
, whereas SRC-1 NRID preferred ER
. Using similar time-resolved fluorescence resonance energy transfer (FRET) technology, we used coactivator NRBs and developed a homogeneous in vitro functional assay to quantitate the ligand-induced recruitment of nuclear coactivator peptides to ER
and ERß LBDs. Using such a FRET assay, we successfully investigated receptor-coactivator interactions and pharmacological profiles of some agonists, partial agonists and SERMs.
 |
RESULTS AND DISCUSSION
|
---|
Assay Design and Optimization
Time resolved FRET assay was used to quantitate the interaction between ER LBD and various coactivator peptides. In the assay, a biotinylated NRB peptide must be recruited to FLAG-tagged ER LBD to bring allophycocyanin (APC) and europium (Eu) close to each other (illustrated in Fig. 1
). An agonist will induce the recruitment of the NRB peptide to ER LBD, resulting in FRET. Compounds with antagonist activity will block the agonist-induced recruitment of the NRB peptide, resulting in decreased FRET. Thus, this homogeneous in vitro assay can be used to quantitate effects of binding of both agonists and antagonists to ER LBDs.

View larger version (34K):
[in this window]
[in a new window]
|
Figure 1. Illustration of the in Vitro Coactivator Recruitment Functional Assay
A, Binding of an agonist to ER LBD (FLAG-tagged) will recruit an NRB peptide (biotinylated) to the complex. Anti-FLAG antibody (Eu-labeled) and streptavidin-conjugated APC (SA-APC) will assemble into the complex, which results in FRET. An antagonist will block the NRB peptide recruitment, resulting in decreased FRET. B, Amino acid sequences of biotinylated NRB peptides used in the experiments.
|
|
Nuclear coactivators can be recruited by ERs in an organ- and cell type-specific manner to achieve optimal biological effects (6, 7, 8, 12, 15, 16). Different classes of coactivator families have been reported to interact with ER
and ERß. The biotinylated NRB peptides used in the experiments were chosen to reflect the diversity of coactivators known to bind ERs (Fig. 1B
). The biotinylated peptides SRC1-II and SRC1-IV represent two different NRBs, both of which are expressed in SRC1a, whereas SRC1-IV is missing in SRC1e. The similar length of NRBs was designed to minimize effect of position or orientation differences of two fluorophores on FRET.
Initial studies were designed to optimize the concentrations of reagents used to achieve FRET. Various concentrations of SRC1-II peptide and streptavidin (SA)-APC were incubated with 1 nM Eu-anti-FLAG antibody, 10 nM FLAG-ER LBD, and 100 nM 17ß-estradiol (E2). The nonspecific binding was measured by a parallel incubation in the absence of the agonist. No ligand-dependent signal was observed when the biotinylated NRB peptide was replaced with a nonbiotinylated peptide (data not shown). As shown in Fig. 2
, varying the concentrations of SRC1-II peptide and SA-APC affected FRET intensity. The signal decreased as the ratio of SRC1-II peptide to SA-APC exceeded 4. At ratios above 4, one has exceeded the relative binding capacity of the streptavidin for biotinylated peptide. Under these conditions some SRC1-II binds to the ER but does not complex with SA-APC, resulting in lower FRET values. The optimal ratio was about 3. Therefore, 100 nM SRC1-II and 30 nM SA-APC were chosen as standard concentrations.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 2. Optimizing the Relative Concentrations of Biotinylated NRB Peptide and SA-APC for Agonist-Induced FRET
Amounts of biotinylated SRC1-II peptide and SA-APC were independently varied to determine optimal FRET conditions. A representative experiment is shown using 5 nM ERß LBD and 100 nM E2. FRET signal was expressed as fluorescence emission intensity ratio at 665 nm/615 nm (multiplied by 104). Nonspecific binding was measured by a parallel incubation in the absence of the agonist. Whereas the ratio of SRC1-II peptide to SA-APC was above 4 and thus exceeded the relative binding capacity of the streptavidin for biotinylated peptide, some SRC1-II binds to the ER LBD but does not complex with SA-APC, resulting in lower FRET values.
|
|
The signal-to-background ratio of the assay remained similar in the pH range of 7.0 to 7.7, with pH 7.2 being optimal for both ER
and ERß (data not shown). The assay tolerated dimethylsulfoxide (DMSO) up to 5% without a significant reduction in signal.
The effect of agonist concentration on FRET was evaluated, using different concentrations of SRC1-II peptide and ERß LBD. E2 induced a concentration-dependent increase in FRET, with an EC50 value that was independent of the amount of SRC1-II peptide used in the assay (Fig. 3A
). The EC50 values for E2 in the presence of 50, 100, and 200 nM SRC1-II were 3.4, 2.9, and 3.5 nM, respectively. A reduction in total FRET was observed at high SRC1-II concentration (200 nM), for reasons stated above. As shown in Fig. 3B
, increasing the concentration of ERß LBD resulted in an increase in the maximal response to E2, whereas the EC50 for E2 remained unchanged (2.03.4 nM, with Hill coefficients of 0.91.2). These results also demonstrated that the assay has high precision with coefficients of variation less than 5%. In dose response experiments, a Z' value of 0.70.9 was achieved even when the signal to background ratio was less than 2-fold as observed at low agonist concentrations. The Z' value is used to assess both specific signal and precision for accurate assay performance (17). A value of above 0.5 indicates that the assay is capable of providing robust, high precision data. The high precision resulted, in part, from the simple liquid handling steps for FRET and also from the ability to normalize the FRET intensity. Another important feature of this assay is that the signal is stable for more than 48 h, which would allow batch processing for high throughput screening applications.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 3. Evaluating the Effect of NRB Peptide and ER Concentrations on Agonist-Induced FRET
A, EC50 of E2 remained the same as the concentration of SRC1-II peptide was varied from 50200 nM. B, Varying the ERß LBD concentration from 520 nM did not significantly affect E2 potency.
|
|
Evaluating Potency and Efficacy of NRB Peptides for ER LBDs
The ability of different NRB peptides to bind to the E2-ER LBD complex was evaluated. As shown in Fig. 4
, these peptides differed significantly in their ability to bind ligand-activated ER LBDs. These experiments used a saturating concentration of agonist; therefore, the EC50 values reflect the affinities of NRB peptides for the ERs. The affinity rank order of NRB peptides for ER
LBD was similar to ERß LBD: SRC1-II
PGC1 SRC1-IV PRIP, CBP. ER
LBD showed slightly higher affinity for CBP than PRIP, whereas ERß LBD exhibited the opposite. The NRB peptides exhibited different efficacies (i.e. maximum FRET signals). However, the efficacy rank order was the same for E2-bound ER
LBD and ERß LBD and paralleled potency rank order. Such efficacy difference should reflect conformation differences in the ER-coactivator peptide complexes so that efficiency of FRET varied. Even though the coactivator peptides have similar length of amino acids at both ends of LXXLL, binding of different coactivator peptides to ER may induce different confirmation changes. In turn, the distance between the fluorescent donor in ER and acceptor in the coactivator peptide may vary among the ER-coactivator peptide complexes.

View larger version (26K):
[in this window]
[in a new window]
|
Figure 4. NRB Peptides Have Different Affinities but the Same Rank Order Preference for ER and ERß
The concentration of NRB peptides was varied in the ER and ERß recruitment assay. The experiments were performed using 100 nM E2 or 10 µM genistein.
|
|
The NRB peptides were also profiled using genistein as the ER agonist. The peptides showed the same affinity rank order for ER
and ERß LBDs as observed with E2. However, the magnitude of FRET seen with ERß LBD was reduced compared with that seen with E2, indicating that genistein is a partial agonist for ERß LBD in this assay system.
The CBP NRB showed a much weaker interaction with ER LBDs than SRC1, which is consistent with literature data (6, 15). The results in Fig. 4
are also consistent with those of Torchia et al. (18), who reported that SRC1-II had higher binding affinity than SRC1-IV for ER. Bramlett et al. (19) reported conflicting results; however, the SRC1-II and SRC1-IV peptides used in their study were 7 and 10 amino acids shorter, respectively, at the N terminus than those used in our assays. The difference in length of the NRB peptides may account for the discrepancy between their results and ours. Adjacent sequences around the LXXLL motif can increase or decrease the affinity of a NRB for NRs (20), hence our decision to use relatively longer NRB peptides.
In the presence of high concentrations of NRB peptides (i.e. above 300 nM), SRC1-II and PGC1 were observed to interact with ER LBDs in the absence of hormone (data not shown). Under these conditions, agonist increased the coactivator peptide affinity for ERs by 3-fold. Similar observations were reported with NRB binding using ELISA and scintillation proximity assays (21). Low affinity ligand-independent interaction of ERs with coactivators may account for basal constitutive transactivation activity of ERs observed in our cell-based functional assay (not shown).
Although the NRB peptides had different affinities for agonist-ER complex, the potency of E2 for ER LBD was similar when high concentrations of the different NRBs were used in the FRET coactivator recruitment assay (Fig. 5
). The efficacy rank order of the NRB peptides was similar to their affinity rank order for ERs. The same EC50 (3.0 nM) was reported in SRC1-II recruitment assay using a time-resolved fluorescence coactivator peptide-binding assay (22). Under these assay conditions, the ability to induce FRET is dependent on agonist concentration. Thus, the EC50 for E2 is independent of the NRB peptide used in the assay, but the efficacy is dependent on which NRB peptide is used.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 5. E2 Has the Same Potency in Recruiting Different NRB Peptides to ERß LBD
E2-mediated NRB recruitment was quantitated using 5 nM ERß LBD and 100 nM of the different NRB peptides.
|
|
Response to Agonists and SERMs
To test affinity and efficacy of agonists for ERs to recruit SRC1-II, E2 and genistein were used in the recruitment assay (Fig. 6
). E2 showed the same affinity and efficacy for ER
and ERß LBDs, which is consistent with the literature data that E2 is a nonselective ER agonist. Genistein showed a more than 10-fold higher selectivity for ERß LBD vs. ER
LBD, but also exhibited partial agonism on ERß LBD and full agonism on ER
LBD (Fig. 6A
). This is in agreement with the results obtained with genistein and multiple NRB peptides (Fig. 4
). Furthermore, in a cell-based functional assay, genistein was reported to induce 5060% of the ERß response seen with E2 (23).
X-ray crystallography studies have revealed a possible structural explanation for genisteins partial agonist profile. In E2-bound ERß, helix 12 appears to cap off the ligand-binding pocket, thus stabilizing the structure and forming a new hydrophobic groove for coactivator interaction (24). Binding of the coactivator is stabilized by a so-called charge clamp with a conserved glutamic acid residue within helix 12 and a lysine residue within helix 3 of ERß. Binding of SERMs such as tamoxifen and raloxifene results in helix 12 blocking the coactivator-binding pocket by mimicking the NRB LXXLL motif. Genistein is completely buried within the hydrophobic core of the protein and binds in a manner similar to that observed forE2. However, in the ERß-geniste in complex, helix12 does not adopt the distinctive agonist position, but, instead, lies in a similar orientation to that induced by ER antagonists (SERMs), thus obstructing the hydrophobic groove for NRB binding (24). Such a suboptimal alignment of the helix is consistent with genisteins partial agonist characterin, the coactivator recruitment assay and demonstrates how ERs transcriptional response to certain bound ligands can be attenuated.
Raloxifene and tamoxifen were tested for both agonist and antagonist activities in the recruitment assay. During a 5-h incubation, neither compound showed agonist activity for ER
or ERß LBD. E2 was then added to the mixture and incubated overnight. Raloxifene completely antagonized E2-induced coactivator recruitment, with 30-fold selectivity for ER
LBD vs. ERß LBD (Fig. 6B
). Tamoxifen also exhibited full antagonism in this assay (data not shown). Similar results have been reported in cell-based assays (23, 25, 26) and in binding assays (27).
Therefore, the FRET coactivator recruitment assay is able to reflect both the binding affinities and cell-based functions of antagonists and to discriminate agonist, partial agonist, and antagonist activities. Moreover, the in vitro functional FRET assay can be used to screen for both agonism and antagonism of compounds in a single run of compound screening.
Correlation with a Cell-Based Functional Assay
The recruitment assay described here provides a simple and robust in vitro functional assay for agonists, partial agonists, and antagonists and is consistent with literature data. To further evaluate its correlation with the function of transcriptional activation, several agonists covering a broad range of potencies from benzoxazole series were tested in both a cell-based reporter gene assay and the FRET in vitro functional assay. The cell-based assay used full-length ERß and an ER-response element (ERE)-reporter system. As shown in Fig. 7
, the rank order of compound potency was similar in the in vitro functional assay and the cell-based functional assay. However, all compounds tested showed higher potency in the cell-based assay than in the in vitro coactivator recruitment assay. Because the FRET assay measures the binding of a single NRB to ligand-bound ERß LBD, the recruitment potencies of ligands in this assay may underestimate the ability of coactivators to induce transcription in a cell-based reporter gene assay. For example, coactivators contain multiple NRBs and can exhibit higher affinity for ER than a single NRB, presumably reflecting the potential for cooperative interactions for enhanced binding and signal amplification (28). Indeed, cocrystallization studies of PPAR
and an 88-amino-acid-long SCR-1 fragment containing two NRBs have shown that one coactivator can bridge across a receptor dimer (29). Most importantly, the rank order of compound potency in the coactivator FRET assay accurately reflected the results of the more complex whole cell transcriptional assay.

View larger version (11K):
[in this window]
[in a new window]
|
Figure 7. Correlation in Agonist Potency between the FRET Assay and a Cell-Based Functional Assay
ER agonists from benzoxazole series were tested in the ERß LBD coactivator recruitment assay and an ERß cell-based transcriptional assay. The EC50 values were determined for each compound and plotted as potency in the transcriptional assay vs. the FRET assay.
|
|
Time resolved FRET utilizes time-gated fluorescence intensity measurements to detect energy transfer from a long-lived fluorophore (in milliseconds for europium, Eu, for example) to a short-lived fluorescent acceptor (e.g. protein allophycocyanin or APC), after excitation with a short pulse of light. Because FRET occurs only when a fluorescent donor and a fluorescent acceptor are in close proximity, such an assay is homogeneous (i.e. no separation and washing needed) and ideal for high-throughput screening in drug discovery. Because Eu has a Stokes shift (the difference between the excitation and emission wavelength maximal) close to 300 nm, roughly 5- to 10-fold larger than that of fluorescent organic dyes, its emission can be detected at a wavelength far away from the excitation wavelength and emission profiles of organic fluorophores that are often present in pharmaceutical compound libraries. The assay quantitated the emission of the donor and acceptor fluorophores, using 615 nm for Eu and 665 nm for APC. By reporting the results ratiometrically, compound quenching effect and variations in reactions are canceled out, resulting in high precision in the assay. Furthermore, in time-resolved fluorescence measurements, background fluorescence is short-lived relative to the delayed measurement (nanoseconds vs. a microsecond), resulting in minimal background signal. Therefore, the unique features of Eu and time resolved FRET result in a very sensitive detection methodology.
In conclusion, the coactivator FRET assay described here was developed in a 384-well high throughput format and successfully used to explore the preference of ERs for different NRBs and to profile some compounds for their agonist and antagonist properties against ERs. The results obtained using this method were comparable to those obtained from a cell-based functional assay and reported in literature, and demonstrate the value of this homogeneous, high throughput method to dissect the mechanisms of interaction between NR and coactivators or ligands and to screen compounds for NR regulation in drug discovery applications.
 |
MATERIALS AND METHODS
|
---|
Materials
Restriction enzymes and modifying enzymes used in molecular biology experiments were purchased from TaKaRa Biomedical (Shiga, Japan). Pfu DNA polymerase was purchased from Stratagene (La Jolla, CA). DNA purification kits and nickel-charged nitrilotriacetic acid agarose were obtained from QIAGEN (Valencia, CA). DH5
competent cells were purchased from Life Technologies, Inc. (Rockville, MD). LANCE Eu-W1024-labeled anti-FLAG antibody, SA-APC, and low-volume 384-well white plates were purchased from Perkin-Elmer Corp. Wallac, Inc. (Gaithersburg, MD). Ninety-six-well cell culture plates (Biocoat Collagen I Cellware) were purchased from BD Biosciences (Bedford, MA). DMEM was from Mediatech (Herndon, VA), and charcoal-stripped FBS was from Biocell (Rancho Dominguez, CA). Chlorophenol red-ß-D-galactopyranoside was purchased from Roche Molecular Biochemicals (Indianapolis, IN). Other reagents were purchased from Sigma.
ER
and ERß Constructs
The human ER
LBD fragment (amino acids 301553) was obtained by PCR amplication. An NdeI site followed by a nucleotide sequence coding for a FLAG tag (underlined) was designed in the forward primer, 5'-GCCATATGGACTACAAGGACGACGATGACTCTAAGAAGAACAGCC-3'. The reverse primer contained a BamHI site after a stop codon (underlined), 5'-GGCGGGATCCTCAAGTGGGCGCATGTAGGCGG-3'. The 0.8-kb amplified DNA product was digested with the appropriate enzymes and subcloned into corresponding sites of a modified pET-28 vector (Novagen, Madison, WI). The vector contained maltose binding protein (MBP) and His tag coding sequences followed by a thrombin cleavage site (LVPRGS) coding sequence before the multiple cloning sites.
The expression plasmid was transformed into BL21(DE3), which were grown at 37 C in the presence 50 µg/ml kanamycin, until induction at OD600 = 1.7 with 250 µM isopropyl-ß-D-thiogalactoside. After induction, the culture was transferred to 20 C and left overnight. Cells were harvested by centrifugation and resuspended in buffer A (25 mM bis-Tris-propane, 10% glycerol, 300 mM NaCl, 1 mM triscarboxyethylphosphine (TCEP), Complete EDTA-free proteinase inhibitors Roche Diagnostics and 0.5 mg/ml lysozyme) followed by sonication and centrifugation at 40,000 x g for 45 min. The supernatant was applied to a nickel-charged nitrilotriacetic acid column and the 6xHis-MBP-FLAG-ER
LBD was eluted in buffer A containing 50 mM imidazole. Fractions containing the fusion protein 6xHis-MBP-FLAG-ER
LBD were combined and desalted on a Sephadex G25 column preequilibrated with buffer B [25 mM bis-Tris propane, 10% vol/vol glycerol, 50 mM NaCl, 1 mM TCEP (pH 9.5) at 4 C]. The fusion protein was then cleavaged with thrombin (5 U thrombin/mg protein) and the resulting MBP and FLAG-ERßLBD were separated by a Source 15Q column preequilibrated with buffer B. FLAG-ER
LBD was eluted with a NaCl gradient of 1100% in buffer C [25 mM bis-Tris propane, 10% vol/vol glycerol, 1 M NaCl, 1 mM TCEP (pH 9.5) at 4 C]. The Source 15Q fractions containing FLAG-ER
LBD were desalted on a Sephadex G25 preequilibrated with buffer B. The purity of FLAG-ER
LBD was estimated to about 95% judged by Commassie stained SDS-PAGE. The mass (calculated, 30,967 Da) of FLAG-ER
LBD was verified (found, 30,965 Da) using an HP 1100 series HPLC connected to an electrospray MSD detector (Hewlett-Packard Co.). Protein concentration was determined by a Bradford-like dye-binding assay (Bio-Rad Laboratories, Inc.). Human FLAG-ERß LBD (amino acids 254510) was obtained in a similar way with higher than 95% purity.
Recruitment Assay
The optimized reaction mixture contained 5 nM of purified FLAG-ER LBD, 30 nM SA-APC, 1.0 nM 77 Eu-FLAG antibody, and 100 nM biotin-SRC1-II peptide in the assay buffer [20 mM HEPES, 50 mM KCl, 1 mM EDTA, 0.05% Nonidet P-40, 1 mM dithiothreitol, and 1 mg/ml BSA (pH 7.2)]. Agonist experiments were performed in a 384-well plate by adding 10 µl of the reaction mixture to 10 µl of agonists (diluted with the assay buffer) using a CyBi-Well liquid dispenser. For determination of antagonist activities, 10 µl of the reaction mixture were added to 5 µl of compounds, after by 5 µl of 16 nM E2 (4 nM final concentration). The reactions were routinely incubated overnight at 4 C because E2 binding to ER reached equilibrium after 9 h (30). The samples were counted using a Wallac, Inc. Victor V 1420 Multilabel Counter with a setting of 50-µsec time delay, excitation at 340 nm, and emission at both 615 nm and 665 nm. Fluorescence intensity ratio at 665 nm/615 nm (multiplied by 104) was used for agonist EC50 plotting directly. For antagonist activities, FRET in the absence of E2 was calculated as 100% inhibition; DMSO control, 0% inhibition. All of the compounds were dissolved in DMSO.
Cell-Based Functional Assay
HEK293 cells were routinely maintained in DMEM supplemented with 10% HFBS, 2 mM L-glutamine, and G418 (0.4 mg/ml). Cells were transfected with a vector containing full-length human ERß and a second vector containing the ß-galactosidase (ß-gal) gene with the vitellogenin estrogen response element (ERE) in its promoter. These expression vectors were constructed with a similar way as described by Ernst et al. (31). The transfection protocol used the calcium phosphate method (Profection Kit, Promega Corp.) according to the suppliers recommendations. The day after transfection cells were trypsinized and seeded onto collagen I coated 96-well culture plates in DMEM (phenol red free) containing 2% FBS (charcoal stripped) and 2 mM L-glutamine at 25,000 cells per well. After approximately 24 h, compounds were added and incubated overnight at 37 C for determination of agonist activities. The level of ß-gal expression was determined using chlorophenol red-ß-D-galactopyranoside as substrate in a lysis buffer (Roche Molecular Biochemicals, Indianapolis, IN) as per the manufacturers instructions.
 |
ACKNOWLEDGMENTS
|
---|
The authors thank Dr. Krister Bamberg for supplying NRB peptides, Stefan Gillström for expressing FLAG-tagged ER
LBD, Linda Hagman for purifying FLAG-tagged ER
LBD, Dr. Philippe Cronet for supplying a modified pET28 plasmid, and Dr. Deborah S. Hartman for reviewing the manuscript critically.
 |
FOOTNOTES
|
---|
Abbreviations: AF, Activation function; APC, allophycocyanin; CBP, CREB binding protein; DMSO, dimethylsulfoxide; E2, 17ß-estradiol; ER, estrogen receptor; ERE, ER- response element; Eu, europium; FRET, fluorescence resonance energy transfer; ß-gal, ß-galatosidase; LBD, ligand binding domain; MBP, maltose binding protein; NcoA, NR coactivator; NR, nuclear receptor; NRB, NR box; NRID, nuclear receptor interacting domain; PGC-1, a coactivator interacting with PPAR
; PPAR, peroxisome proliferator-activated receptor; PRIP/RAP250, PPAR-interacting protein; SA, streptavidin; SERMs, selective ER modulators; SRC, steroid receptor coactivator; TCEP, triscarboxyethylphosphine.
Received for publication September 23, 2002.
Accepted for publication November 25, 2002.
 |
REFERENCES
|
---|
- McKenna NJ, OMalley BW 2002 Minireview: nuclear receptor coactivatorsan update. Endocrinology 143:24612465[Abstract/Free Full Text]
- Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93105[Medline]
- Roy AK, Tyagi RK, Song CS, Lavrovsky Y, Ahn SC, Oh TS, Chatterjee B 2001 Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann NY Acad Sci 949:4457[Abstract/Free Full Text]
- Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H 1996 A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:8794[Medline]
- Glass CK, Rose DW, Rosenfeld MG 1997 Nuclear receptor coactivators. Curr Opin Cell Biol 9:222232[CrossRef][Medline]
- Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H 2001 Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem 276:66956702[Abstract/Free Full Text]
- Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M 1996 p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 93:1154011545[Abstract/Free Full Text]
- Torchia J, Glass C, Rosenfeld MG 1998 Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 10:373383[CrossRef][Medline]
- Kalkhoven E, Valentine JE, Heery DM, Parker MG 1998 Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J 17:232243[Abstract/Free Full Text]
- Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE 1998 A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 273:2764527653[Abstract/Free Full Text]
- Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK 2000 Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 275:1351013516[Abstract/Free Full Text]
- Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson JA 2000 Cloning and characterization of RAP250, a novel nuclear receptor coactivator J Biol Chem 275:53085317[Abstract/Free Full Text]
- Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP 2000 Modulation of estrogen receptor-
transcriptional activity by the coactivator PGC-1. J Biol Chem 275:1630216308[Abstract/Free Full Text]
- Zhou G, Cummings R, Li Y, Mitra S, Wilkinson HA, Elbrecht A, Hermes JD, Schaeffer JM, Smith RG, Moller DE 1998 Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Mol Endocrinol 12:15941604[Abstract/Free Full Text]
- Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733736[CrossRef][Medline]
- Puigserver P, Wu ZD, Park CW, Graves R, Wright M, Spiegelman BMA 1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829839[Medline]
- Zhang JH, Chung TD, Oldenburg KR 1999 A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:6773[Medline]
- Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677684[CrossRef][Medline]
- Bramlett KS, Wu Y, Burris TP 2001 Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol Endocrinol 15:909922[Abstract/Free Full Text]
- Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR 1998 Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12:33433356[Abstract/Free Full Text]
- Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan STS, Go NF, Hart CP, Schatz PJ 2000 Selection of estrogen receptor ß- and thyroid hormone receptor ß-specific coactivator-mimetic peptides using recombinant peptide libraries. Mol Endocrinol 14:605622[Abstract/Free Full Text]
- Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup MR 1998 Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 12:302313[Abstract/Free Full Text]
- Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JÅ, Nilsson S 1998 Differential response of estrogen receptor
and estrogen receptor ß to partial estrogen agonists/antagonists. Mol Pharmacol 54:105112[Abstract/Free Full Text]
- Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M 1999 Structure of the ligand-binding domain of oestrogen receptor ß in the presence of a partial agonist and a full antagonist. EMBO J 18:46084618[Abstract/Free Full Text]
- Shen ES, Meade EH, Perez MC, Deecher DC, Negro-Vilar A, Lopez FJ 1998 Expression of functional estrogen receptors and galanin messenger ribonucleic acid in immortalized luteinizing hormone-releasing hormone neurons: estrogenic control of galanin gene expression. Endocrinology 139:939948[Abstract/Free Full Text]
- Fitzpatrick SL, Berrodin TJ, Jenkins SF, Sindoni DM, Deecher DC, Frail DE 1999 Effect of estrogen agonists and antagonists on induction of progesterone receptor in a rat hypothalamic cell line. Endocrinology 140:39283937[Abstract/Free Full Text]
- Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JÅ 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor ß. Endocrinology 139:42524263[Abstract/Free Full Text]
- Wong CW, Komm B, Cheskis BJ 2001 Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. Biochemistry 40:67566765[CrossRef][Medline]
- Nolte RT, Wisely GB, Westin S, Cobbs JE, Lambert MH, Kurokawa R, Rosenfeldt MG, Willson TM, Glass GK, Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-
. Nature 395:137143[CrossRef][Medline]
- Grill HJ, Manz B, Belovsky O, Krawielitzki B, Pollow K 1983 Comparison of [3H]oestradiol and [125I]oestradiol as ligands for oestrogen receptor determination. J Clin Chem Clin Biochem 21:175179[Medline]
- Ernst M, Parker MG, Rodan GA 1991 Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element. Mol Endocrinol 5:1597606[Abstract]